As this N-terminal cysteine-rich domain shares substantial sequence similarity with Wnt binding domain of FZD receptors, SFRP2 was initially considered to antagonize the Wnt signaling by preventing binding of Wnt ligands to FZD receptors, which may inhibit tumor development (13). Here, SFRP2 is linked to neoplasm.